Myelodysplastic Syndrome

Explore the newest developments in clinical research and treatment for myelodysplastic syndromes (MDS). Cancer Nursing Today has the latest clinical findings and perspectives on personalized risk prediction models for MDS, genetic mutations related to MDS progression, donor lymphocyte infusions, and more. From clinical trials and screening techniques to the latest treatments, learn how MDS care is evolving.

Investigating a Personalized Prediction Model to Risk Stratify MDS Patients

Investigating a Personalized Prediction Model to Risk Stratify MDS Patients

Ariel Jones

Myelodysplastic Syndrome | October 12, 2021

Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for prognostic systems that incorporate clinical, pathologic, and molecular data to predict survival more accurately in this patient group. In a study published in the Journal of Clinical Oncology, researchers sought to develop a prognostic model for patients with MDS receiving a variety of MDS-targeted treatments. First, they enrolled 1,471 patients with comprehensively annotated clinical and molecular data in a training cohort and analyzed data using machine learning techniques. They ...

Advertisement

Latest News

Investigating a Personalized Prediction Model to Risk Stratify MDS Patients

Investigating a Personalized Prediction Model to Risk Stratify MDS Patients

Ariel Jones

Myelodysplastic Syndrome | October 12, 2021

Survival rates for myelodysplastic syndromes (MDS) varies widely – from months to decades – highlighting the need for ...

Evaluating Donor Lymphocyte Infusion by Relapse Level in MDS

Evaluating Donor Lymphocyte Infusion by Relapse Level in MDS

Ariel Jones

Myelodysplastic Syndrome | October 7, 2021

For post-transplant disease control in patients with myelodysplastic syndromes (MDS), donor lymphocyte infusion (DLI) has ...

Oral Azacitidine Reduces Transfusion Dependence in Low-Risk MDS

Oral Azacitidine Reduces Transfusion Dependence in Low-Risk MDS

Ariel Jones

Myelodysplastic Syndrome | September 13, 2021

Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine ...

Pevonedistat Plus Azacitidine Shows Clinical Efficacy in Higher-Risk MDS and Low-Blast AML

Pevonedistat Plus Azacitidine Shows Clinical Efficacy in Higher-Risk MDS and Low-Blast AML

Ariel Jones

Myelodysplastic Syndrome | August 31, 2021

Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival ...

Comparing 5-Azacitidine Versus Transplant in Older Patients With MDS

Comparing 5-Azacitidine Versus Transplant in Older Patients With MDS

Ariel Jones

Myelodysplastic Syndrome | August 11, 2021

In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity ...

Enasidenib With or Without Azacitidine Promising in Patients with IDH2-Mutated MDS

Enasidenib With or Without Azacitidine Promising in Patients with IDH2-Mutated MDS

Keightley Amen

Myelodysplastic Syndrome | June 23, 2021

Treatment with enasidenib, a small molecule inhibitor of mutant IDH2, showed promising clinical activity in patients with ...

Advertisement

Knowledge Hubs

GI Cancer

GI Cancer

GVHD

GVHD

Gyn-Onc

Gyn-Onc

Multiple Myeloma

Multiple Myeloma

Conference Highlights

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Automated Coaching with NP Follow-up Effectively Reduced Symptom Burden

June 16, 2022

Did Updated FDA Guidance Increase Inclusion of Patients With Brain Metastases in Breast Cancer Trials?

June 14, 2022

Palliative Care Consults Can Be Improved in Patients With Metastatic Breast Cancer

June 14, 2022

Study Identifies Ways to Increase Representation of Black Patients in Breast Cancer Clinical Trials

June 14, 2022

Caregivers, Patients Have Different Decision-Making Support Needs

June 16, 2022

Nurse Monitoring Could Prevent Symptoms Related to Targeted, Immune Therapies

June 16, 2022

Advertisement

Advertisement

Popular Stories

Researchers Discover Signature to Predict Response to Pembrolizumab

Keightley Amen

Conferences | June 2, 2022

The new data is being used to develop a biomarker tool to predict the efficacy of neoadjuvant pembrolizumab.

Study Examines COVID-19 Vaccine Efficacy in Patients With Breast Cancer

Keightley Amen

Conferences | June 2, 2022

Many studies are examining COVID-19's impact on particular subgroups of patients with cancer.

Recognizing Compassion Fatigue

Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®

Best Practices | April 22, 2022

Oncology nurses experience stress from many different directions—time pressures, nursing shortages, complex cancer ...

670 Madison Ave.

Manalapan, NJ 07726

Connect

Our Network

Blood Cancers Today

GU Oncology Now

Urban Health Today

About Us

Editorial Policy

© 2022 Mashup Media, LLC. All rights reserved.

Terms of Use | Privacy Policy